(NASDAQ: VALN) Valneva Se's forecast annual revenue growth rate of 32.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Valneva Se's revenue in 2025 is $211,429,545.On average, 1 Wall Street analysts forecast VALN's revenue for 2025 to be $34,710,777,955, with the lowest VALN revenue forecast at $34,710,777,955, and the highest VALN revenue forecast at $34,710,777,955. On average, 1 Wall Street analysts forecast VALN's revenue for 2026 to be $59,745,930,616, with the lowest VALN revenue forecast at $59,745,930,616, and the highest VALN revenue forecast at $59,745,930,616.
In 2027, VALN is forecast to generate $78,353,402,021 in revenue, with the lowest revenue forecast at $78,353,402,021 and the highest revenue forecast at $78,353,402,021.